FindTrial
Sign In

Study on the Effectiveness and Safety of a Skincare Product for Reducing Acne

To evaluate the in vivo safety and efficacy of Skin care formulation in terms of reduction in acne breakouts and redness on healthy human subjects - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080244
Enrollment
36
Registered
2025-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: D ACNE soap (S23DN008) (S24DN013) (S24DN008): The Product is applied to wash the face, back and body of subject once in a day at morning for the period of 28 days Control Intervention1

Sponsors

Glenmark Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Indian male and female subjects. 2)Healthy subjects 3)Skin is healthy on the studied anatomic unit 4)Having oily to mixed oily skin type. 5)Having mild to moderate acne on face or body/back. 6)Having visible pores. 7)Having white heads and black heads.

Exclusion criteria

Exclusion criteria: 1. Being pregnant or breastfeeding or having stopped to breastfeed in the past three months. 2. Having refused to give his/her assent by not signing the consent form and Informed consent form 3. Taking part in another study liable to interfere with this study 4. Being known diabetic case 5. Known asthma case 6. Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis) 7. Being known thyroid case 8. Being epileptic. 9. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes or corticosteroid by any route (the only medication permitted is paracetamol) 10. Known case of hypersensitivity. 11. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products. 12. Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.

Design outcomes

Primary

MeasureTime frame
Reduction in acne (live/occurring) breakouts and rednessTimepoint: Baseline, Day 1, Day 3, Day 5, Day 7, Day 10, Day 12, Day 14, Day 21, Day 28—

Secondary

MeasureTime frame
Reduction in pore size, sebum, white heads and blackheadsTimepoint: Baseline, Day 1, Day 3, Day 5, Day 7, Day 10, Day 12, Day 14, Day 21, Day 28—

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

poojayadav@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026